Thomas James Doyle insider trades: Kura Oncology (KURA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | KURA | ↓ Sell | 4,607 | $10.50 | $48K | Direct | Sep 29, 2026 (1d) |
| Jan 27, 2026 | KURA | ↓ Sell | 7,142 | $8.46 | $60K | Direct | Jan 27, 2026 (0d) |
| Nov 14, 2025 | KURA | ↓ Sell | 4,539 | $11.18 | $51K | Direct | Nov 14, 2025 (0d) |
| Sep 29, 2025 | KURA | ↓ Sell | 4,541 | $8.94 | $41K | Direct | Sep 29, 2025 (0d) |
| Jan 28, 2025 | KURA | ↓ Sell | 4,949 | $7.87 | $39K | Direct | Jan 28, 2025 (0d) |
| Jan 29, 2024 | KURA | ↓ Sell | 2,318 | $17.80 | $41K | Direct | Jan 31, 2024 (2d) |
| Jan 27, 2023 | KURA | ↓ Sell | 1,548 | $13.89 | $22K | Direct | Jan 31, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other KURA insiders
Open-market trades in the last 12 months
About Thomas James Doyle's insider trades
Thomas James Doyle is SVP, Finance & Accounting at Kura Oncology (KURA). Since Jan 27, 2023, Thomas has reported no open-market purchases and 7 sales worth $302K on SEC Form 4. In the last 12 months: 3 sales ($160K).
Their filings also include grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KURA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.